Clinical trials: Obese Non Diabetic
Overweight or Obesity
A Study of BGM1812 Injection in Healthy and Non-diabetic Overweight or Obese Chinese Participants
The purpose of this study is to evaluate the tolerability , safety and pharmacodynamics of BGM1812 administered subcutaneously in healthy and non-diabetic overweight or obese Chinese participants, and to investigate the…
- Trial name
- NCT07294235
- Testing
- BGM1812
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- BrightGene Bio-Medical Technology Co., Ltd.
Non-diabetic Obesity
PEG-rhGH and Semaglutide Combination Therapy in Non-Diabetic Obese Adults
This study aims to evaluate the efficacy and safety of PEG-rhGH Injection combined with Semaglutide Injection versus Semaglutide Injection monotherapy in improving body composition (lean body mass, fat mass, etc.) in non-diabetic…
- Trial name
- NCT06863363
- Testing
- PEG-rhGH Injection + Semaglutide Injection, Semaglutide Injection
- Where
- China
- Volunteers
- 212 people
- Sponsor
- Shanghai Zhongshan Hospital
Non-Alcoholic Fatty Liver Disease
Extension of ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With (NAFLD)
This extension study will assess the safety and effects of 24 weeks of treatment with ALT-801 in diabetic and non-diabetic subjects with overweight and obesity and non-alcoholic fatty liver disease (NAFLD).
- Trial name
- NCT05292911
- Testing
- ALT-801
- Where
- 13 sites in United States
- Volunteers
- 64 people
- Sponsor
- Altimmune, Inc.
The Study Focused on the Vascular Effects of Semaglutide in Both Diabetic and Non-diabetic Patients, Obesity &Amp; Overweight
Coronary Flow Reserve Changes After Semaglutide Treatment
The goal of this observational study is to learn about the effects of semaglutide to coronary artery flow in diabetic and non-diabetic patients.
- Trial name
- NCT07190144
- Where
- Turkey (Türkiye)
- Volunteers
- 122 people
- Sponsor
- Ekrem Bilal Karaayvaz
Diabetes, Obesity
A 12-WEEK TITRATE STUDY TO EVALUATE SAFETY, TOLERABILITY AND PHARMACODYNAMICS OF PF-06882961 IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND IN NON-DIABETIC ADULTS WITH OBESITY
This study will assess tolerability, safety, and pharmacodynamics (PD) of twice daily (BID) administration of PF- 06882961 in adult participants with Type 2 Diabetes Mellitus (T2DM) who are treated with metformin and in…
- Trial name
- NCT04617275
- Testing
- PF-06882961
- Where
- 38 sites in United States
- Volunteers
- 151 people
- Sponsor
- Pfizer
Overweight, Obesity
A Study to Measure Stomach Emptying in Overweight Non-diabetic and Diabetic Participants Using Tirzepatide
The purpose of this study is to learn more about how tirzepatide affects stomach emptying in overweight/very overweight participants. Participants include those without diabetes and those with type 2 diabetes.
- Conditions
- Overweight, Obesity, Diabetes Mellitus, Type 2
- Trial name
- NCT04407234
- Testing
- Tirzepatide, Acetaminophen
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Eli Lilly and Company
Obesity
Efficacy of D-allulose on Weight and Fat Loss and Insulin Resistance in Non-diabetic Obese Subjects
Prospective, randomized, double-blind, controlled-trial 30 subjects in each groups Group - I consume pure D-allulose 5 g 3 times a day before meal to right after meal (with any liquid) and Group - II control group with…
- Trial name
- NCT02988999
- Testing
- D-allulose, erythritol
- Where
- Thailand
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Chiang Mai University
Dyslipidemias, Overweight or Obesity
Efficacy of Pigmented Rice on Reducing Cardiometabolic Risk Factors Among Filipino Adults
The primary purpose of this clinical trial is to investigate whether the consumption of pigmented rice (black rice) in the diet improves cardiovascular health, specifically body weight, lipids, and glucose levels.
- Conditions
- Dyslipidemias, Overweight or Obesity, Hyperglycaemia (Non Diabetic)
- Trial name
- NCT06092632
- Testing
- Pigmented rice, White Rice
- Where
- Philippines
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University of Santo Tomas
Weight Loss, Obesity
The Effects of Exenatide (Byetta ) on Energy Expenditure and Weight Loss in Nondiabetic Obese Subjects
Exenatide is an incretin-like drug that has been approved for treatment of type 2 diabetes; it improves glycemia by increasing insulin and decreasing glucagon secretion by pancreatic islet cells and delaying gastric emptying.
- Trial name
- NCT00856609
- Testing
- Byetta (exenatide), Weight loss, Metabolic Chamber
- Where
- United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Non-arteritic Anterior Ischemic Optic Neuropathy Obesity, Obesity
NAION in Non-Diabetic Obese Patients Using GLP-1 Receptor Agonists: A Real-World Study
Non-arteritic anterior ischemic optic neuropathy (NAION) is one of the most common causes of sudden, painless, usually unilateral vision loss in adults over 50 years of age, and no proven effective treatment exists.
- Trial name
- NCT07846956
- Testing
- GLP-1 Receptor Agonist Therapy
- Where
- Turkey (Türkiye)
- Volunteers
- 28 people
- Sponsor
- Istanbul Saglik Bilimleri University
Healthy, Non-diabetic Overweight or Obese
A Study of BGM0504 Tablets in Healthy and Non-diabetic Overweight or Obese Chinese Subjects
A Randomized, Double-Blind, Placebo-Controlled, Single/Multiple-dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BGM0504 Tablets Orally Administered in Healthy and Non-diabetic Overweight or Obese…
- Trial name
- NCT07239973
- Testing
- BGM0504 tablets
- Where
- China
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- BrightGene Bio-Medical Technology Co., Ltd.
Overweight , Obesity
Phase 2 Study to Evaluate the Efficacy and Safety of MWN109 Injection in Non-Diabetic Participants With Overweight
This study is a multicenter, randomized, double-blind, placebo-controlled phase II study conducted in China. It aims to evaluate the efficacy and safety of MWN109 injection in non-diabetic overweight or obese participants.
- Trial name
- NCT07791537
- Testing
- MWN109 1, MWN109 2, MWN109 3
- Where
- China
- Volunteers
- 125 people
- Sponsor
- Shanghai Minwei Biotechnology Co., Ltd
Diabetes Mellitus Type 2, Non Alcoholic Fatty Liver Disease
Amlexanox for Type 2 Diabetes and Obesity
This study involves the use of a research drug, Amlexanox, for the treatment of type 2 diabetes, insulin resistance, obesity and non-alcoholic fatty liver disease (NAFLD). Amlexanox is taken orally in a pill three times a day.
- Conditions
- Diabetes Mellitus Type 2, Non Alcoholic Fatty Liver Disease, Obesity
- Trial name
- NCT01842282
- Testing
- Amlexanox
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of Michigan
Diastolic Dysfunction, Obesity
The Effect of Addition of Metformin In Obese Non- Diabetic Patients With Heart Failure With Preserved Ejection Fraction
Diabetes mellitus people have a higher incidence of cardiovascular disease, and the results of cardiovascular events are worse. Heart failure and diabetes both have a worse prognosis, with a 1.5-2 times increased risk of death.
- Trial name
- NCT05847244
- Testing
- Metformin
- Where
- 2 sites in Egypt
- Volunteers
- 80 people
- Sponsor
- Sara ElAdawy
Hypercholesterolemia, Diabetes
Does Simvastatin Affect Insulin Sensitivity in Dyslipidemic Type 2 Diabetic Patients?
We aimed to address the issue whether statins affect insulin resistance. To this end, we combined the available state-of-the art technology for detailed assessment of both whole-body and tissue specific insulin sensitivity in…
- Conditions
- Hypercholesterolemia, Diabetes, Cardiovascular Disease
- Trial name
- NCT00704314
- Testing
- Simvastatin
- Where
- Austria
- Volunteers
- 20 people
- Sponsor
- Medical University of Vienna